Champions Oncology (NASDAQ:CSBR) Stock Crosses Above Fifty Day Moving Average - Should You Sell?

Key Points

• Champions Oncology crossed above its fifty day moving average, trading as high as $6.18 (50‑day MA $6.00; 200‑day MA $6.49) on a volume of 6,065 shares.
• Analyst sentiment is negative: Weiss Ratings downgraded the stock from "hold (c-)" to "sell (d-)" and MarketBeat reports a consensus "Sell" rating.
• Fundamentals and ownership: the company has a market cap of $85.84 million and a negative P/E (-38.63), while institutional investors own about 41.3% and several funds (including Vanguard and Acadian) recently increased or initiated stakes.

Champions Oncology, Inc. (NASDAQ:CSBR - Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.00 and traded as high as $6.18. Champions Oncology shares last traded at $6.18, with a volume of 6,065 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Champions Oncology from a "hold (c-)" rating to a "sell (d-)" rating in a report on Monday, March 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of "Sell".

Champions Oncology Price Performance

The stock has a market cap of $85.84 million, a P/E ratio of -38.63 and a beta of 0.40. The company's 50 day simple moving average is $6.00 and its 200 day simple moving average is $6.49.

Institutional Investors Weigh In On Champions Oncology

Several large investors have recently bought and sold shares of the company. Mink Brook Asset Management LLC bought a new stake in Champions Oncology in the fourth quarter valued at approximately $555,000. Essex Investment Management Co. LLC bought a new stake in shares of Champions Oncology during the fourth quarter worth $126,000. Vanguard Group Inc. increased its position in shares of Champions Oncology by 1.9% during the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company's stock worth $2,158,000 after acquiring an additional 6,229 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Champions Oncology during the second quarter worth $103,000. Finally, Acadian Asset Management LLC grew its position in Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 8,814 shares in the last quarter. Institutional investors own 41.30% of the company's stock.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.